291 related articles for article (PubMed ID: 20932818)
1. Improving community participation to eliminate lymphatic filariasis in American Samoa.
King JD; Zielinski-Gutierrez E; Pa'au M; Lammie P
Acta Trop; 2011 Sep; 120 Suppl 1():S48-54. PubMed ID: 20932818
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of effectiveness of diethylcarbamazine/albendazole combination in reduction of Wuchereria bancrofti infection using multiple infection parameters.
Wamae CN; Njenga SM; Ngugi BM; Mbui J; Njaanake HK
Acta Trop; 2011 Sep; 120 Suppl 1():S33-8. PubMed ID: 20933491
[TBL] [Abstract][Full Text] [Related]
3. Impact of five annual rounds of mass drug administration with diethylcarbamazine and albendazole on Wuchereria bancrofti infection in American Samoa.
Liang JL; King JD; Ichimori K; Handzel T; Pa'au M; Lammie PJ
Am J Trop Med Hyg; 2008 Jun; 78(6):924-8. PubMed ID: 18541771
[TBL] [Abstract][Full Text] [Related]
4. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
de Rochars MB; Kanjilal S; Direny AN; Radday J; Lafontant JG; Mathieu E; Rheingans RD; Haddix AC; Streit TG; Beach MJ; Addiss DG; Lammie PJ
Am J Trop Med Hyg; 2005 Nov; 73(5):888-94. PubMed ID: 16282299
[TBL] [Abstract][Full Text] [Related]
5. Endpoints for lymphatic filariasis programs.
Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.
Fraser M; Taleo G; Taleo F; Yaviong J; Amos M; Babu M; Kalkoa M
Am J Trop Med Hyg; 2005 Oct; 73(4):753-8. PubMed ID: 16222021
[TBL] [Abstract][Full Text] [Related]
7. Community empowerment in the control of lymphatic filariasis in Misima, Milne Bay Province using diethylcarbamazine in combination with albendazole.
Selve BP; Bwadua S; Misa M; James K; Usurup JP; Turner P; Melrose W; Yad W; Samuel R; Eddie C
P N G Med J; 2000; 43(3-4):183-7. PubMed ID: 11939299
[TBL] [Abstract][Full Text] [Related]
8. Reaching endpoints for lymphatic filariasis elimination- results from mass drug administration and nocturnal blood surveys, South Gujarat, India.
Modi A; Gamit S; Jesalpura BS; Kurien G; Kosambiya JK
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005476. PubMed ID: 28369129
[TBL] [Abstract][Full Text] [Related]
9. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration.
Lau CL; Sheridan S; Ryan S; Roineau M; Andreosso A; Fuimaono S; Tufa J; Graves PM
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005914. PubMed ID: 28922418
[TBL] [Abstract][Full Text] [Related]
10. Persistence of lymphatic filarial infection in the paediatric population of rural community, after six rounds of annual mass drug administrations.
Sunish IP; Munirathinam A; Kalimuthu M; Ashok Kumar V; Tyagi BK
J Trop Pediatr; 2014 Jun; 60(3):245-8. PubMed ID: 24343822
[TBL] [Abstract][Full Text] [Related]
11. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
[TBL] [Abstract][Full Text] [Related]
12. Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
Ramaiah KD; Vanamail P; Yuvaraj J; Das PK
Trans R Soc Trop Med Hyg; 2011 Aug; 105(8):431-7. PubMed ID: 21601901
[TBL] [Abstract][Full Text] [Related]
13. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018.
Willis GA; Mayfield HJ; Kearns T; Naseri T; Thomsen R; Gass K; Sheridan S; Graves PM; Lau CL
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008854. PubMed ID: 33253148
[TBL] [Abstract][Full Text] [Related]
14. Albendazole for mass drug administration to eliminate lymphatic filariasis.
Sabesan S
Lancet Infect Dis; 2006 Nov; 6(11):684-5. PubMed ID: 17067916
[No Abstract] [Full Text] [Related]
15. Imported bancroftian filariasis: diethylcarbamazine response and benzimidazole susceptibility of Wuchereria bancrofti in dynamic cross-border migrant population targeted by the National Program to Eliminate Lymphatic Filariasis in South Thailand.
Bhumiratana A; Pechgit P; Koyadun S; Siriaut C; Yongyuth P
Acta Trop; 2010 Feb; 113(2):121-8. PubMed ID: 19835831
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Thakur PA; Gupta A; Ingole NS; Lazdins-Helds JK
Parasitol Res; 2017 Oct; 116(10):2683-2694. PubMed ID: 28785847
[TBL] [Abstract][Full Text] [Related]
17. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.
Mayfield HJ; Sartorius B; Sheridan S; Howlett M; Martin BM; Thomsen R; Tofaeono-Pifeleti R; Viali S; Graves PM; Lau CL
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012236. PubMed ID: 38935622
[TBL] [Abstract][Full Text] [Related]
18. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis.
Wkly Epidemiol Rec; 2004 Oct; 79(40):358-65. PubMed ID: 15631012
[No Abstract] [Full Text] [Related]
19. The role of albendazole in programmes to eliminate lymphatic filariasis.
Ottesen EA; Ismail MM; Horton J
Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168
[TBL] [Abstract][Full Text] [Related]
20. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
McLure A; Graves PM; Lau C; Shaw C; Glass K
Epidemics; 2022 Sep; 40():100591. PubMed ID: 35816826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
